Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: A retrospective analysis

Sougioultzis, Stavros; Syrios, John; Xynos, Ioannis; Bovaretos, Nikolaos; Kosmas, Christos; Sarantonis, John; Dokou, Anna; Tzivras, Dimitrios; Zografos, George; Felekouras, Evangelos; Papalambros, Efstathios; Tsavaris, Nikolas

doi:10.1016/j.ejso.2011.01.019

Cited by 49 publications

(49 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have been several studies suggesting that CA72-4 is associated with advanced stages of gastrointestinal cancer and poor prognosis [12][13][14][15]. In our study, CA72-4 had the second highest sensitivity for peritoneal dissemination, following CA125.…”

Section: Discussionsupporting

confidence: 49%

“…Univariate and multivariate analyses of prognostic factors for overall survival were also performed. Fourteen putative clinicopathological variables were selected, based on factors identified by previous studies [4,15]. Patient-related factors included age, sex, and pre-treatment performance status according to the European Cooperative Oncology Group (ECOG).…”

Section: Evaluation Of Patients' Clinical Statusmentioning

confidence: 99%

“…However, in these studies, the number of patients with peritoneal metastasis was relatively small. Although serum CA72-4 has also been reported to be elevated in the advanced stages of gastric cancer [12][13][14][15], the clinical relevance of CA72-4 in peritoneal metastasis remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

et al. 2011

View full text Add to dashboard Cite

Background Serum tumor markers have been shown to correlate with the clinical status of patients with advanced gastric cancer. However, the clinical significance of each tumor marker in patients with peritoneal dissemination has not been fully verified. Methods Four serum markers, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, CA125, and CA72-4, were periodically measured in 102 patients with peritoneal dissemination who received combination intravenous and intraperitoneal chemotherapy. The initial values at diagnosis and after treatment were analyzed in association with clinicopathological factors, response to chemotherapy, and overall survival. Results The sensitivities of CEA, CA19-9, CA125, and CA72-4 for peritoneal metastasis at the initial diagnosis were 19, 36, 46, and 45%, respectively. The CA125 level was significantly correlated with the degree of peritoneal dissemination and the existence of malignant ascites. Patients with ovarian metastasis showed significantly higher levels of CA72-4. The median survival time of patients with an elevated CA125 level was significantly shorter than that of patients with a normal CA125 level (36.7 vs. 16.6 months, p \ 0.001). Multivariate analysis showed that the degree of peritoneal metastasis and an elevated CA125 level were independent prognostic factors. Normalization of the CA125 level after 3 courses of chemotherapy was correlated with reduced ascites and improved survival.Conclusions Serum CA125 and CA72-4 are clinically useful markers in diagnosis, evaluating the efficacy of chemotherapy, and predicting the prognosis of patients with peritoneal dissemination. From an academic point of view, periodic measurements of these markers are warranted in gastric cancer patients with possible peritoneal dissemination.

show abstract

Section: Discussionsupporting

confidence: 49%

Section: Evaluation Of Patients' Clinical Statusmentioning

confidence: 99%

See 1 more Smart Citation

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Similar associations with survival have been established in chronic myeloid and lymphocytic leukaemias (Weinberg et al, 2007;Goldaniga et al, 2008) and small cell lung cancer (SCLC) (You et al, 2008;Danner et al, 2010). In recent clinical trials, elevated serum LDH has been shown as an independent predictor of overall survival in advanced or metastatic cancer of the breast (Brown et al, 2012), prostate (Scher et al, 2009;Gravis et al, 2014), colorectum (Bar et al, 2014), oesophagus (Polee et al, 2003), pancreas (Tas et al, 2001), ovary (Schneider et al, 1998), nasopharynx (Jin et al, 2013), gastric adenocarcinoma (Sougioultzis et al, 2011), hepatocellular carcinoma (HCC) (Faloppi et al, 2014), renal cell carcinoma (Armstrong et al, 2012) and melanoma (Balch et al, 2004;Weide et al, 2012). The inverse association with overall survival in solid tumours were shown in a recent meta-analysis, with HR for overall death of 1.7 (95% CI: 1.62-1.79) (Petrelli et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

1009 Serum lactate dehydrogenase and survival following cancer diagnosis

Wulaningsih¹,

Holmberg²,

Garmo³

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

“…Previous studies demonstrated that CA 19-9 is associated with the prognosis of patients with gastric cancer, and that it could be used as a prognostic indicator and postoperative monitoring index of gastric cancer (17). Sougioultzis et al (18) conducted a retrospective analysis of 114 cases of gastric cancer, and demonstrated that serum CA 19-9 level is significantly increased in stage IV patients compared with that in stages I, II and III, and preoperative CA19-9 expression is associated with recurrence and metastasis. Marrelli et al (19) monitored the level of CEA and CA19-9 in recurrent and non-recurrence groups following radical gastrectomy, and revealed that the recurrence group was positive for least one tumor marker.…”

Section: Discussionmentioning

confidence: 99%

Associations between CA19‑9 and CA125 levels and human epidermal growth factor receptor 2 overexpression in patients with gastric cancer

et al. 2018

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the association between serum carbohydrate antigen (CA)19-9 and CA125 levels, and human epidermal growth factor receptor 2 (HER2) expression in patients with gastric cancer, as well as to identify any correlation between them and the risk of recurrence and metastasis. A total of 256 patients were enrolled in the present study, and 219 patients were followed-up to investigate recurrence and metastasis of gastric cancer. Immunohistochemistry was used to detect HER-2 in gastric adenocarcinoma and paracancerous tissues. The positive rate of CA19-9 and CA125 in stages III/IV was higher compared with that in stages I/II. The positive rate of HER2 in distinct stages of gastric cancer was not statistically different. Serum CA19-9 and CA125 were not associated with the positive expression of HER2. The recurrence and metastasis of CA19-9, CA125 and HER2-positive gastric cancer were increased compared with those experienced by CA19-9, CA125 and HER2-negative patients. Age, stage and preoperative tumor markers were associated with 3-year prognosis of gastric cancer. HER2 [odds ratio (OR)=2.55] and CA19-9 (OR=1.22) were independent prognostic factors in patients with gastric cancer. CA19-9, CA125 and HER2 may be used to predict the recurrence or metastasis of gastric cancer. The combined detection may be able to improve the sensitivity and efficiency of predicting the recurrence or metastasis of gastric cancer. Preoperative positive serum for CA19-9 and CA125 were associated with poor prognosis in patients with gastric cancer. CA19-9 and HER2 were independent prognostic factors of gastric cancer.

show abstract

Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: A retrospective analysis

Cited by 49 publications

References 29 publications

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

1009 Serum lactate dehydrogenase and survival following cancer diagnosis

Associations between CA19‑9 and CA125 levels and human epidermal growth factor receptor 2 overexpression in patients with gastric cancer

Contact Info

Product

Resources

About